Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial
Antje Dietrich, Michael Andreeff, Lydia Koi, Ralf Bergmann, M. Schubert, Lena Schreiner, Steffen Löck, Wiebke Sihver, Robert Freudenberg, Sandra Hering, Hans‐Jürgen Pietzsch, Jörg Steinbach, Jörg Kotzerke, Michaël Baumann, Mechthild Krause
Abstract
BACKGROUND AND PURPOSE: Y-labeled anti-EGFR antibody (Cetuximab) with clinically relevant fractionated radiotherapy in a preclinical trial using head and neck squamous cell carcinoma xenograft tumors. MATERIALS AND METHODS: Y-Cetuximab were performed to test the curative potential. RESULTS: Y-Cetuximab at a dose that did not result in permanent tumor inactivation in previous experiments, led to substantially increased tumor control compared to radiotherapy alone. CONCLUSION: Our results indicate that combination of radiolabeled therapeutics with clinically relevant fractionated radiotherapy has a remarkable potential to improve curative treatment outcome. Application of some radiation dose prior to injection may improve drug uptake and enable patient stratification and treatment personalization via a corresponding PET-tracer during therapy.